Bresagen Limited
Records under this name other than patents Bresagen Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,334,138 | Methods and compositions for feeder-free pluripotent stem cell media containing human serum Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,623,650 | Methods and compositions for feeder-free pluripotent stem cell media containing human serum Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,432,104 | Methods for the culture of human embryonic stem cells on human feeder cells Formerly held Lapsed on the fee record Ended Oct 7, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 7, 2020 | From the USPTO record |
| US 7,737,253 | Human cancer stem cell culture compositions comprising Erbb2 variants and methods of use thereof Formerly held Lapsed on the fee record Ended Jun 15, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 15, 2018 | From the USPTO record |
| US 7,445,931 | Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs Formerly held Lapsed on the fee record Ended Nov 4, 2016 · High confidence | Lapsed on the fee record | Ended Nov 4, 2016 | High confidence |
| US 7,201,899 | Materials and methods for management of hyperacute rejection in human xenotransplantation Term ended Term ended Jan 28, 2015 · From the USPTO record | Term ended | Term ended Jan 28, 2015 | From the USPTO record |
| US 6,849,448 | Pigs and pig cells having an inactivated α 1,3-galactosyl transferase gene Term ended Term ended Jan 27, 2014 · From the USPTO record | Term ended | Term ended Jan 27, 2014 | From the USPTO record |
| US 6,749,833 | Design and planning system for improving the survival rate of injected structures Formerly held Lapsed on the fee record Ended Jun 15, 2012 · From the USPTO record | Lapsed on the fee record | Ended Jun 15, 2012 | From the USPTO record |
| US 6,994,841 | Relating to magnetic resonance imaging Formerly held Term ended Ended no later than Mar 9, 2010 · From the USPTO record | Term ended | Ended no later than Mar 9, 2010 | From the USPTO record |
| US 6,465,616 | Interleukin-5 antagonist Lapsed on the fee record Ended Oct 15, 2006 · From the USPTO record | Lapsed on the fee record | Ended Oct 15, 2006 | From the USPTO record |